Lonza reported a solid set of H1 figures, which included the investments in the company’s future, especially in Pharma, Biotech & Nutrition. Specialty Ingredients were impacted by the carve-out costs, whereas the gross profit was quite stable. Nevertheless, the H1 figures were above our expectations, but consensus was not fully met.
24 Jul 2019
The expected mixed picture
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
The expected mixed picture
Lonza Group AG (0QNO:LON) | 0 0 0.0% | Mkt Cap: 22,735m
- Published:
24 Jul 2019 -
Author:
Martin Schnee -
Pages:
3
Lonza reported a solid set of H1 figures, which included the investments in the company’s future, especially in Pharma, Biotech & Nutrition. Specialty Ingredients were impacted by the carve-out costs, whereas the gross profit was quite stable. Nevertheless, the H1 figures were above our expectations, but consensus was not fully met.